Treatment of ocular disorders by gene therapy

• We examine the promises and challenges of applying gene therapy to ocular diseases.
• We revise preclinical and clinical studies in which ocular gene therapy was applied.
• The eye presents advantages for gene therapy: accessibility and ease of evaluation.
• Viral vectors are the most common gene delivery systems for ocular diseases.
• Gene replacement therapy is the most widely used in clinical approach.

Gene therapy to treat ocular disorders is still starting, and current therapies are primarily experimental, with most human clinical trials still in research state, although beginning to show encouraging results. Currently 33 clinical trials have been approved, are in progress, or have been completed. The most promising results have been obtained in clinical trials of ocular gene therapy for Leber Congenital Amaurosis, which have prompted the study of several ocular diseases that are good candidates to be treated with gene therapy: glaucoma, age-related macular degeneration, retinitis pigmentosa, or choroideremia. The success of gene therapy relies on the efficient delivery of the genetic material to target cells, achieving optimum long-term gene expression. Although viral vectors have been widely used, their potential risk associated mainly with immunogenicity and mutagenesis has promoted the design of non-viral vectors. In this review, the main administration routes and the most studied delivery systems, viral and non-viral, for ocular gene therapy are presented. The primary ocular disease candidates to be treated with gene therapy have been also reviewed, including the genetic basis and the most relevant preclinical and clinical studies.

Figure optionsDownload high-quality image (66 K)Download as PowerPoint slide